Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 59.26B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.14B | |
| -0.86% | -4.48% | +26.38% | +33.20% | 42.91B | |
| +0.01% | +0.66% | +351.47% | +688.38% | 44.13B | |
| -1.03% | -1.97% | +2.48% | +98.17% | 40.79B | |
| -0.54% | +2.93% | +9.50% | +50.41% | 30.77B | |
| -2.68% | +5.11% | +33.11% | +19.50% | 29.31B | |
| +1.98% | -6.71% | -28.06% | +333.29% | 23.71B | |
| Average | -0.14% | -0.64% | +52.27% | +158.47% | 43.6B | |
| Weighted average by Cap. | +0.08% | -0.40% | +57.37% | +150.06% |
Employees
51
